Market Definition 

Hemoglobinopathies are a group of disorders inherited in which there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) and thalassemia are blood disorders caused by abnormal hemoglobin that damages and deforms red blood cells. 

Global hemoglobinopathies market is estimated to reach $7.2 billion by 2027, growing at a CAGR of 10.9% till 2027. 

Market Dynamics 

The rising prevalence of hemoglobinopathies is boosting the market growth. For instance, approximately 7% of the worldwide population have hemoglobinopathies and are the most common monogenic diseases. Sickle Cell Disease (SCD) is the most common inherited blood disorder in the United States. According to the Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 Americans in 2020. Sickle Cell Disease occurs among 1 out of every 16,300 Hispanic-American births. The prevalence of beta-thalassemia globally is around 288,000, with an incidence of 60,000 births per year. Beta-thalassemia is prevalent in developing countries of Africa, South Asia, Southeast Asia, the Mediterranean region and the Middle East. The total prevalence of beta-thalassemia in the European Union and the United States is estimated to be approximately 19,000 patients. Every year approximately 100,000 children are born with Thalassemia Major around the world, of which 10,000 are born in India. Further, favorable government programs related to hemoglobinopathy are a key driving factor of the market. However, product recall might hamper the market growth. Moreover, an increasing clinical trial for hemoglobinopathies therapy would provide lucrative opportunities for the market in coming years. 

Market Segmentation 

The global hemoglobinopathies market is mainly classified based on type, end-user, and test type. Type is further segmented into Thalassemia, Sickle Cell Disease, and Others. By end-user, the market is divided into Hospitals, Diagnostics Laboratories, and Others. By test type, the market is further divided into Genetic Testing, Routine Red Blood Cell (RBC) Count, Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), and Others. 

 Based on Type, sickle cell disease was dominating the hemoglobinopathies market in 2020, owing to the rising incidence of sickle cell disease. For instance, in 2019, around 100,000 people in the U.S. have sickle cell disease (SCD), and more than 20 million people have sickle cell disease globally. Moreover, increasing regulatory approval for the therapy to treat sickle cell disease is driving the market demand. For instance, the U.S. Food and Drug Administration has approved Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. Oxbryta is an inhibitor of deoxygenated sickle hemoglobin polymerization, which is the central abnormality in sickle cell disease. 

Regional Analysis 

Based on geography, the global hemoglobinopathies market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided into the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America is expected to dominate the hemoglobinopathies market in 2021 due to the rising incident and prevalence of hemoglobinopathies, commercialization of regulatory approval of hemoglobinopathies therapy, and increasing clinical studies on hemoglobinopathies therapy. For instance, Imara Inc., a clinical-stage biopharmaceutical company that develops and commercializes therapeutics to treat patients suffering from inherited genetic disorders of hemoglobin, has introduced the company’s Forte Phase 2b clinical trials of IMR-687 for patients with beta-thalassemia. IMR-687 is designed to have a multimodal mechanism action on red blood cells, white blood cells, adhesion mediators and other cell types. 

Competitive landscape 

Key players operating in the hemoglobinopathies industry include Bio-Rad Laboratories, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd, PerkinElmer Inc., Sysmex Corporation, Novartis AG, Emmaus Medical, Bristol-Myers Squibb Company, ApoPharma Inc, Gamida Cell, and Acceleron Pharma, Inc. 

Raising funds for the development of hemoglobinopathies products, commercialization of regulatory approved hemoglobinopathies therapy, increasing clinical trials for the hemoglobinopathies therapy, and the collaboration between companies and private foundation for the development of hemoglobinopathies therapy products are some of the strategies adopted by the major companies. For instance, on February 17, 2021, Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation. Based on the agreement, the foundation will provide funding support for the development of a single-administration, in vivo gene therapy for the treatment of sickle cell disease (SCD). The objectives of the project is to expand access to healthcare in low-resource settings in an effort to address sickle cell disease (SCD) life-threatening genetic disease. 

Hemoglobinopathies Market Key Segments: 

By Type 

• Thalassemia 
• Sickle Cell Disease 
• Others 

By End-User 

• Hospitals 
• Diagnostics Laboratories 
• Others 

By Test Type 

• Genetic Testing 
• Routine Red Blood Cell (RBC) Count 
• Hemoglobin Isoelectric Focusing (Hb IEF) 
• Hemoglobin electrophoresis (Hb ELP) 
• Others 

Key Global Hemoglobinopathies Industry Players 

• Bio-Rad Laboratories, Inc. 
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd 
• PerkinElmer Inc. 
• Sysmex Corporation 
• Novartis AG 
• Emmaus Medical 
• Bristol-Myers Squibb Company 
• ApoPharma Inc 
• Gamida Cell 
• Acceleron Pharma, Inc 

What Report Provides 

• Full in-depth analysis of the parent Industry 
• Important changes in market and its dynamics 
• Segmentation details of the market 
• Former, on-going, and projected market analysis in terms of volume and value 
• Assessment of niche industry developments 
• Market share analysis 
• Key strategies of major players 
• Emerging segments and regional growth potential